Pharmaco(epi)genomics in ovarian cancer

Pharmacogenomics

Volumn 9, Issue 12, 2008, Pages 1825-1834

  Paige, Adam J W ^a   Brown, Robert ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

drug resistance; miRNA; polymorphisms; promoter methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; CYTOCHROME P450; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM COMPLEX; PROTEIN KINASE B; PROTEIN MLH1; PROTEIN P53; TAXANE DERIVATIVE; TOPOTECAN; XERODERMA PIGMENTOSUM GROUP A PROTEIN; ANTINEOPLASTIC AGENT;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG CLEARANCE; DRUG METABOLISM; DRUG RESPONSE; EPIGENETICS; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENETIC POLYMORPHISM; GERM LINE; HUMAN; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PHENOTYPE; PROTEIN METHYLATION; REVIEW; DRUG RESISTANCE; FEMALE; GENETIC EPIGENESIS; GENETIC MARKER; GENETICS; METHODOLOGY; OVARY TUMOR; PHARMACOGENETICS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENETIC MARKERS; HUMANS; OVARIAN NEOPLASMS; PHARMACOGENETICS;

EID: 61549089987     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.12.1825     Document Type: Review

References (82)

1. Agarwal R, Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 3, 502-516 (2003). (Pubitemid 37328838)
2. Gore ME, Fryatt I, Wiltshaw E, Dawson T: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36, 207-211 (1990). (Pubitemid 20061287)
3. Markman M, Rothman R, Hakes T et al.: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9, 389-393 (1991).
4. Watters JW, McLeod HL: Cancer pharmacogenomics: current and future applications. Biochim. Biophys. Acta 1603, 99-111 (2003). (Pubitemid 36262943)
5. Green H: Pharmacogenomics of importance for paclitaxel chemotherapy. Pharmacogenomics 9, 671-674 (2008).
6. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R: Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J. Clin. Oncol. 25, 4528-4535 (2007). (Pubitemid 350035308)
7. Bosch TM, Huitema AD, Doodeman VD et al.: Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin. Cancer Res. 12, 5786-5793 (2006).
8. Henningsson A, Marsh S, Loos WJ et al.: Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin. Cancer Res. 11, 8097-8104 (2005). (Pubitemid 41698753)
9. Nakajima M, Fujiki Y, Kyo S et al.: Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J. Clin. Pharmacol. 45, 674-682 (2005). (Pubitemid 40696210)
10. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C: Mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin. Cancer Res. 12, 854-859 (2006). (Pubitemid 43259868)
11. Obata H, Yahata T, Quan J, Sekine M, Tanaka K: Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer. Anticancer Res. 26, 2227-2232 (2006). (Pubitemid 43980177)
12. Gréen H, Soderkvist P, Rosenberg P, Horvath G, Peterson C: ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J. Pharm. Sci. 97, 2045-2048 (2008).
13. Johnatty SE, Beesley J, Paul J et al.: ABCB1 (MDR1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin. Cancer Res. 14(17), 5594-5601 (2008).
14. Ludwig AH, Kupryjanczyk J: Does MDR-1 G2677T/A polymorphism really associate with ovarian cancer response to paclitaxel chemotherapy? Clin. Cancer Res. 12, 6204 (2006). (Pubitemid 44703788)
15. Sissung TM, Mross K, Steinberg SM et al.: Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur. J. Cancer 42, 2893-2896 (2006). (Pubitemid 44755257)
16. Tran A, Jullien V, Alexandre J et al.: Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1 and GST polymorphisms. Clin. Pharmacol. Ther. 79, 570-580 (2006). (Pubitemid 43833447)
17. Soyama A, Saito Y, Hanioka N et al.: Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol. Pharm. Bull. 24, 1427-1430 (2001). (Pubitemid 33133761)
18. Park JS, Yamamoto W, Sekikawa T et al.: Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. Int. J. Oncol. 20, 333-338 (2002).
19. Morari EC, Lima AB, Bufalo NE, Leite JL, Granja F, Ward LS: Role of glutathione-Stransferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J. Cancer Res. Clin. Oncol. 132, 521-528 (2006). (Pubitemid 43938336)
20. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC: Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 63, 1311-1316 (2003). (Pubitemid 36348710)
21. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J. Natl Cancer Inst. 84, 1512-1517 (1992).
22. Yu JJ, Mu C, Lee KB et al.: A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat. Res. 382, 13-20 (1997). (Pubitemid 28376643)
23. Park DJ, Zhang W, Stoehlmacher J et al.: ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin. Adv. Hematol. Oncol. 1, 162-166 (2003). (Pubitemid 34013872)
24. Kang S, Ju W, Kim JW et al.: Association between excision repair crosscomplementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp. Mol. Med. 38, 320-324 (2006). (Pubitemid 44033245)
25. Steffensen KD, Waldstrom M, Jeppesen U, Brandslund I, Jakobsen A: Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int. J. Gynecol. Cancer 18(4), 702-710 (2007).
26. Smith S, Su D, Rigault de la Longrais IA et al.: ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J. Clin. Oncol. 25, 5172-5179 (2007). (Pubitemid 350232247)
27. Saldivar JS, Lu KH, Liang D et al.: Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol. Oncol. 107, S223-S229 (2007). (Pubitemid 47487477)
28. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33, 357-365 (2003).
29. Sullivan A, Syed N, Gasco M et al.: Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23, 3328-3337 (2004). (Pubitemid 38669822)
30. Santos AM, Sousa H, Portela C et al.: TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem. Biophys. Res. Commun. 340, 256-262 (2006). (Pubitemid 41827674)
31. Galic V, Willner J, Wollan M et al.: Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 46, 239-247 (2007). (Pubitemid 46155319)
32. Bartel F, Jung J, Bohnke A et al.: Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin. Cancer Res. 14, 89-96 (2008). (Pubitemid 351377982)
33. Gadducci A, Di Cristofano C, Zavaglia M et al.: P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res. 26, 687-693 (2006). (Pubitemid 43206035)
34. Hall J, Paul J, Brown R: Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert Rev. Mol. Med. 6, 1-20 (2004). (Pubitemid 43118253)
35. Marsh S, King CR, McLeod HL, Paul J, Gifford G, Brown R: ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. Clin. Cancer Res. 12, 4127; author reply 4127-4129 (2006). (Pubitemid 44078102)
36. Vasey PA, Jayson GC, Gordon A et al.: Phase III randomized trial of docetaxelcarboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl Cancer Inst. 96, 1682-1691 (2004). (Pubitemid 39585637)
37. Klose RJ, Bird AP: Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 31, 89-97 (2006).
38. Glasspool RM, Teodoridis JM, Brown R: Epigenetics as a mechanism driving polygenic clinical drug resistance. Br. J. Cancer 94, 1087-1092 (2006).
39. Corney DC, Nikitin AY: MicroRNA and ovarian cancer. Histol. Histopathol. 23, 1161-1169 (2008).
40. Zhang L, Huang J, Yang N et al.: MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl Acad. Sci. USA 103, 9136-9141 (2006). (Pubitemid 43902545)
41. Blower PE, Chung JH, Verducci JS et al.: MicroRNAs modulate the chemosensitivity of tumor cells. Mol. Cancer Ther. 7, 1-9 (2008).
42. Iorio MV, Visone R, Di Leva G et al.: MicroRNA signatures in human ovarian cancer. Cancer Res. 67, 8699-8707 (2007). (Pubitemid 47437445)
43. Meng F, Henson R, Lang M et al.: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130, 2113-2129 (2006). (Pubitemid 43816961)
44. Nam EJ, Yoon H, Kim SW et al.: MicroRNA expression profiles in serous ovarian carcinoma. Clin. Cancer Res. 14, 2690-2695 (2008).
45. Chong S, Whitelaw E: Epigenetic germline inheritance. Curr. Opin. Genet. Dev. 14, 692-696 (2004). (Pubitemid 39505376)
46. Suter CM, Martin DI, Ward RL: Germline epimutation of MLH1 in individuals with multiple cancers. Nat. Genet. 36, 497-501 (2004).
47. Chan TL, Yuen ST, Kong CK et al.: Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat. Genet. 38, 1178-1183 (2006). (Pubitemid 44470364)
48. Heijmans BT, Kremer D, Tobi EW, Boomsma DI, Slagboom PE: Heritable rather than age-related environmental and stochastic factors dominate variation in DNA methylation of the human IGF2/H19 locus. Hum. Mol. Genet. 16, 547-554 (2007). (Pubitemid 46522617)
49. Fraga MF, Ballestar E, Paz MF et al.: Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl Acad. Sci. USA 102, 10604-10609 (2005). (Pubitemid 41061601)
50. Plumb JA, Steele N, Finn PW, Brown R: Epigenetic approaches to cancer therapy. Biochem. Soc. Trans. 32, 1095-1097 (2004). (Pubitemid 39655556)
51. Strathdee G, MacKean MJ, Illand M, Brown R: A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18, 2335-2341 (1999). (Pubitemid 29192710)
52. Helleman J, van Staveren IL, Dinjens WN et al.: Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer 6, 201 (2006). (Pubitemid 44314367)
53. Branch P, Masson M, Aquilina G, Bignami M, Karran P: Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene 19, 3138-3145 (2000). (Pubitemid 30455925)
54. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R: Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5- azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 60, 6039-6044 (2000).
55. Furlan D, Carnevali I, Marcomini B et al.: The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin. Cancer Res. 12, 3329-3336 (2006). (Pubitemid 43910876)
56. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R: The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 10, 4420-4426 (2004). (Pubitemid 38878884)
57. Teodoridis JM, Hall J, Marsh S et al.: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 65, 8961-8967 (2005). (Pubitemid 41377387)
58. Taverna P, Liu L, Hanson AJ, Monks A, Gerson SL: Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother. Pharmacol. 46, 507-516 (2000).
59. Wang C, Horiuchi A, Imai T et al.: Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J. Pathol. 202, 215-223 (2004). (Pubitemid 38208659)
60. Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA: High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet. Cytogenet. 159, 114-122 (2005).
61. Venkitaraman AR: Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108, 171-182 (2002). (Pubitemid 34161138)
62. Narod SA, Foulkes WD: BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 4, 665-676 (2004).
63. Zhou C, Huang P, Liu J: The carboxylterminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells. Biochem. Biophys. Res. Commun. 336, 952-960 (2005). (Pubitemid 41338360)
64. Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D: The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int. J. Oncol. 22, 1169-1173 (2003).
65. Quinn JE, James CR, Stewart GE et al.: BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin. Cancer Res. 13, 7413-7420 (2007).
66. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97, 2187-2195 (2003). (Pubitemid 36444059)
67. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T: Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581-2586 (2008). (Pubitemid 351556255)
68. DAndrea AD: The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatinsensitive ovarian cancers. Cell Cycle 2, 290-292 (2003).
69. Taniguchi T, Tischkowitz M, Ameziane N et al.: Disruption of the Fanconi anemia- BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 9, 568-574 (2003). (Pubitemid 36597103)
70. Lim SL, Smith P, Syed N et al.: Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. Br. J. Cancer 98, 1452-1456 (2008). (Pubitemid 351543586)
71. Wang Z, Li M, Lu S, Zhang Y, Wang H: Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol. Ther. 5, 256-260 (2006).
72. Lu J, Getz G, Miska EA et al.: MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005). (Pubitemid 40839735)
73. Shell S, Park SM, Radjabi AR et al.: Let-7 expression defines two differentiation stages of cancer. Proc. Natl Acad. Sci. USA 104, 11400-11405 (2007). (Pubitemid 47175152)
74. Taylor DD, Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110, 13-21 (2008). (Pubitemid 351853251)
75. Kelly MG, Alvero AB, Chen R et al.: TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 66, 3859-3868 (2006).
76. Chen R, Alvero AB, Silasi DA et al.: Regulation of IKKβ by miR-199a affects NF-kB activity in ovarian cancer cells. Oncogene 27(34), 4712-4723 (2008).
77. Chen R, Alvero AB, Silasi DA, Steffensen KD, Mor G: Cancers take their Toll - the function and regulation of Toll-like receptors in cancer cells. Oncogene 27, 225-233 (2008).
78. Yang H, Kong W, He L et al.: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68, 425-433 (2008). (Pubitemid 351380068)
79. Hall JA, Brown R, Paul J: An exploration into study design for biomarker identification: issues and recommendations. Cancer Genomics Proteomics 4, 111-119 (2007). (Pubitemid 46807338)
80. UK Ovarian Cancer statistics, from Cancer Research UK. http://info.cancerresearchuk.org/cancerstats/types/ovary/
81. Chemotherapy guidelines for ovarian cancer, from the Scottish Intercollegiate Guidelines Network. www.sign.ac.uk/pdf/sign75.pdf
82. Guidance on the use of paclitaxel in the treatment of ovarian cancer, from the National Institute for Clinical Excellence. www.nice.org.uk/nicemedia/ pdf/55-Paclitaxel-ovarianreviewfullguidance.pdf